VERTEX PHARMACEUTICALS INC / MA Cost of Revenue
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Cost of Revenue of $489.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA cost of goods and services sold for the quarter ending 2026-06-30 was $489.20M, a 20.05% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA cost of goods and services sold for the quarter ending 2026-03-31 was $392.80M, a 8.21% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA cost of goods and services sold for the quarter ending 2025-12-31 was $466.00M, a 10.06% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA cost of goods and services sold for the quarter ending 2025-09-30 was $414.80M, a 5.65% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA cost of goods and services sold for fiscal 2025 was $1.65B, a 7.89% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA cost of goods and services sold for fiscal 2024 was $1.53B, a 21.26% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA cost of goods and services sold for fiscal 2023 was $1.26B, a 16.84% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA cost of goods and services sold for fiscal 2022 was $1.08B, a 19.48% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $489.20M 10-Q · filed 2026-08-04 | $882.00M 10-Q · filed 2026-08-04 | $1.35B derived: sum of 3 quarters · filed 2026-08-04 | $1.76B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $392.80M 10-Q · filed 2026-05-05 | $858.80M derived: sum of 2 quarters · filed 2026-05-05 | $1.27B derived: sum of 3 quarters · filed 2026-05-05 | $1.68B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $466.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $880.80M derived: sum of 2 quarters · filed 2026-02-13 | $1.29B derived: sum of 3 quarters · filed 2026-08-04 | $1.65B 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | $414.80M 10-Q · filed 2025-11-04 | $822.30M derived: sum of 2 quarters · filed 2026-08-04 | $1.19B 10-Q · filed 2025-11-04 | $1.61B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $407.50M 10-Q · filed 2026-08-04 | $770.50M 10-Q · filed 2026-08-04 | $1.19B derived: sum of 3 quarters · filed 2026-08-04 | $1.59B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $363.00M 10-Q · filed 2026-05-05 | $786.40M derived: sum of 2 quarters · filed 2026-05-05 | $1.18B derived: sum of 3 quarters · filed 2026-05-05 | $1.55B derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $423.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $816.00M derived: sum of 2 quarters · filed 2026-02-13 | $1.19B derived: sum of 3 quarters · filed 2026-02-13 | $1.53B 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $392.60M 10-Q · filed 2025-11-04 | $764.50M derived: sum of 2 quarters · filed 2025-11-04 | $1.11B 10-Q · filed 2025-11-04 | $1.48B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | $371.90M 10-Q · filed 2025-08-05 | $714.50M 10-Q · filed 2025-08-05 | $1.08B derived: sum of 3 quarters · filed 2026-02-13 | $1.40B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | $342.60M 10-Q · filed 2025-05-06 | $710.60M derived: sum of 2 quarters · filed 2026-02-13 | $1.03B derived: sum of 3 quarters · filed 2026-02-13 | $1.34B derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | $368.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $686.70M derived: sum of 2 quarters · filed 2026-02-13 | $995.30M derived: sum of 3 quarters · filed 2026-02-13 | $1.26B 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | $318.70M 10-Q · filed 2024-11-05 | $627.30M derived: sum of 2 quarters · filed 2024-11-05 | $894.20M 10-Q · filed 2024-11-05 | $1.18B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $308.60M 10-Q · filed 2024-08-02 | $575.50M 10-Q · filed 2024-08-02 | $858.80M derived: sum of 3 quarters · filed 2025-02-13 | $1.15B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $266.90M 10-Q · filed 2024-05-07 | $550.20M derived: sum of 2 quarters · filed 2025-02-13 | $839.60M derived: sum of 3 quarters · filed 2025-02-13 | $1.10B derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $283.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $572.70M derived: sum of 2 quarters · filed 2025-02-13 | $834.50M derived: sum of 3 quarters · filed 2025-02-13 | $1.08B 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $289.40M 10-Q · filed 2023-11-07 | $551.20M derived: sum of 2 quarters · filed 2023-11-07 | $797.00M 10-Q · filed 2023-11-07 | $1.04B derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $261.80M 10-Q · filed 2023-08-02 | $507.60M 10-Q · filed 2023-08-02 | $755.00M derived: sum of 3 quarters · filed 2024-02-15 | $991.50M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $245.80M 10-Q · filed 2023-05-02 | $493.20M derived: sum of 2 quarters · filed 2024-02-15 | $729.70M derived: sum of 3 quarters · filed 2024-02-15 | $957.70M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $247.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $483.90M derived: sum of 2 quarters · filed 2024-02-15 | $711.90M derived: sum of 3 quarters · filed 2024-02-15 | $904.20M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $236.50M 10-Q · filed 2022-10-28 | $236.51M 10-Q · filed 2021-11-03 | $464.50M derived: sum of 2 quarters · filed 2022-10-28 | $656.80M 10-Q · filed 2022-10-28 | $656.81M 10-Q · filed 2021-11-03 | $859.90M derived: sum of 4 quarters · filed 2022-10-28 | ||
| 2021-06-30 | $228.00M 10-Q · filed 2022-08-05 | $227.97M 10-Q · filed 2021-07-30 | $420.30M 10-Q · filed 2022-08-05 | $420.30M 10-Q · filed 2021-07-30 | $623.40M derived: sum of 3 quarters · filed 2022-08-05 | $809.58M derived: sum of 4 quarters · filed 2022-08-05 | ||
| 2021-03-31 | $192.30M 10-Q · filed 2022-05-06 | $192.33M 10-Q · filed 2021-04-30 | $395.40M derived: sum of 2 quarters · filed 2022-05-06 | $581.58M derived: sum of 3 quarters · filed 2022-05-06 | $766.10M derived: sum of 4 quarters · filed 2022-05-06 | |||
| 2020-12-31 | $203.10M 10-K · filed 2021-02-11 | $389.28M derived: sum of 2 quarters · filed 2021-11-03 | $573.80M derived: sum of 3 quarters · filed 2021-11-03 | $736.30M 10-K · filed 2023-02-10 | ||||
| 2020-09-30 | $186.18M 10-Q · filed 2021-11-03 | $370.70M derived: sum of 2 quarters · filed 2021-11-03 | $533.20M 10-Q · filed 2021-11-03 | $718.21M derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | $184.52M 10-Q · filed 2021-07-30 | $347.02M 10-Q · filed 2021-07-30 | $532.03M derived: sum of 3 quarters · filed 2021-07-30 | $663.94M derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2020-03-31 | $162.50M 10-Q · filed 2021-04-30 | $347.51M derived: sum of 2 quarters · filed 2021-04-30 | $479.42M derived: sum of 3 quarters · filed 2021-04-30 | $615.16M derived: sum of 4 quarters · filed 2021-04-30 | ||||
| 2019-12-31 | $185.01M 10-K · filed 2021-02-11 | $316.93M derived: sum of 2 quarters · filed 2021-02-11 | $452.67M derived: sum of 3 quarters · filed 2021-02-11 | $547.80M 10-K · filed 2022-02-09 | $547.76M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $131.91M 10-K · filed 2021-02-11 | $267.65M derived: sum of 2 quarters · filed 2021-02-11 | $362.75M 10-Q · filed 2020-10-30 | $485.04M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $135.74M 10-K · filed 2021-02-11 | $230.83M 10-Q · filed 2020-07-31 | $353.12M derived: sum of 3 quarters · filed 2021-02-11 | $464.38M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $95.09M 10-K · filed 2021-02-11 | $217.38M derived: sum of 2 quarters · filed 2021-02-11 | $328.64M derived: sum of 3 quarters · filed 2021-02-11 | $433.02M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $122.29M 10-K · filed 2020-02-13 | $233.54M derived: sum of 2 quarters · filed 2020-02-13 | $337.93M derived: sum of 3 quarters · filed 2020-02-13 | $409.54M 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $111.25M 10-K · filed 2020-02-13 | $215.64M derived: sum of 2 quarters · filed 2020-02-13 | $287.25M 10-Q · filed 2019-10-31 | $371.30M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-06-30 | $104.38M 10-K · filed 2020-02-13 | $176.00M 10-Q · filed 2019-08-01 | $260.05M derived: sum of 3 quarters · filed 2020-02-13 | $332.92M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-03-31 | $71.61M 10-K · filed 2020-02-13 | $155.66M derived: sum of 2 quarters · filed 2020-02-13 | $228.54M derived: sum of 3 quarters · filed 2020-02-13 | $299.74M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | $84.05M 10-K · filed 2019-02-13 | $156.93M derived: sum of 2 quarters · filed 2019-02-13 | $228.13M derived: sum of 3 quarters · filed 2019-02-13 | $275.12M 10-K · filed 2020-02-13 | ||||
| 2017-09-30 | $72.87M 10-K · filed 2019-02-13 | $144.08M derived: sum of 2 quarters · filed 2019-02-13 | $191.07M 10-Q · filed 2018-10-25 | |||||
| 2017-06-30 | $71.20M 10-K · filed 2019-02-13 | $118.19M derived: sum of 2 quarters · filed 2019-02-13 | ||||||
| 2017-03-31 | $46.99M 10-K · filed 2019-02-13 | |||||||
| 2016-12-31 | $210.46M 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |